Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the
presence of autoantibodies against nuclear antigens, immune complex deposition, and …

Background Belimumab, the first biologic approved for the treatment of systemic lupus
erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE …

Results Of 257 enrolled patients, 255 were treated (safety population: n= 123 switched from
placebo-to-belimumab; n= 132 remained on belimumab); 245 (97%) patients completed the …

Abstract Background Belimumab (Benlysta) is currently approved for the treatment of active
Lupus despite standard therapy. Few data are available on the efficacy of this drug in lupus …

Objectives To evaluate the long-term safety and efficacy of belimumab in patients with
systemic lupus erythematosus (SLE) from Japan and South Korea. Methods In this phase III …

Background Biologic agents (also termed biologics or biologicals) are becoming
increasingly important in the treatment of immune‐mediated diseases. However, the …

The development of biological therapies has had an impact on the management of several
medical conditions. Their use in systemic lupus erythematosus (SLE), however, remains …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple
systems with a range of clinical presentations caused by the production of antibodies …

ABSTRACT Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated
autoimmune disease which can potentially involve several organs and systems. The …

Belimumab (Benlysta®) is a fully humanized monoclonal antibody that inhibits B lymphocyte
stimulator (BLyS, also known as B cell-activating factor of the tumor necrosis factor family) …